Caixin
Apr 28, 2022 08:00 AM

Chongqing Lummy Pharmaceutical Co.,Ltd. Posted 29 Million Yuan Net Loss in First Quarter of 2022

Chongqing Lummy Pharmaceutical Co.,Ltd. (重庆莱美药业股份有限公司) (300006.SZ) reported a net loss of 29 million yuan in the first quarter of 2022, reversing a net profit of 52 million yuan for the same period in the previous year.

Meanwhile, the company posted 198.7 million yuan in revenue, down 44.8% year-on-year.

At the end of the reporting period, it had 3 billion yuan in total assets and 825.9 million yuan in total liabilities, with a liability-to-asset ratio of 27.5%.

Share this article
Open WeChat and scan the QR code
NEWSLETTERS
Get our CX Daily, weekly Must-Read and China Green Bulletin newsletters delivered free to your inbox, bringing you China's top headlines.

We ‘ve added you to our subscriber list.

Manage subscription
PODCAST
Caixin Deep Dive: Why Singapore Sovereign Fund Sues Chinese EV-Maker Nio
00:00
00:00/00:00